AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21492424 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ultrasound comet-tail sign and NT-proBNP
Number of subjects: 218
Study 21492428 — intervention group
Group type: EXPERIMENTAL
Intervention: AlgaeCal 1
Number of subjects: 158
Study 21492428 — intervention group
Group type: EXPERIMENTAL
Intervention: AlgaeCal 2
Number of subjects: 158
Study 21492428 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 158
Study 21492763 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip treatment
Number of subjects: 107
Study 21493699 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent placement and tracheobronchoplasty (TBP)
Number of subjects: 12
Study 21493699 — intervention group
Group type: COMPARATOR
Intervention: Stent placement
Number of subjects: 12
Study 21493699 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheobronchoplasty (TBP)
Number of subjects: 12
Study 21493737 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD-Unclassified smokers
Number of subjects: 2500
Study 21493737 — intervention group
Group type: EXPERIMENTAL
Intervention: LLN-Unclassified smokers
Number of subjects: 2500
Study 21493737 — intervention group
Group type: COMPARATOR
Intervention: Smoking control subjects
Number of subjects: 2500
Study 21493737 — intervention group
Group type: COMPARATOR
Intervention: Subjects with COPD
Number of subjects: 2500
Study 21493789 — intervention group
Group type: EXPERIMENTAL
Intervention: Software-aided image with bone suppression and soft-tissue visualization algorithm
Number of subjects: 368
Study 21493789 — intervention group
Group type: EXPERIMENTAL
Intervention: Software-aided image
Number of subjects: 368
Study 21493789 — intervention group
Group type: COMPARATOR
Intervention: Standard radiograph
Number of subjects: 368
Study 21493817 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg daily
Number of subjects: 8781
Study 21493817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8781
Study 21494121 — intervention group
Group type: EXPERIMENTAL
Intervention: SG1 (standard group) - underwent total mesorectal excision (TME) 6 weeks after CRT
Number of subjects: 144
Study 21494121 — intervention group
Group type: EXPERIMENTAL
Intervention: SG2 (study group) - received 2 cycles of modified FOLFOX-6 (mFOLFOX-6) followed by TME 3 to 5 weeks later
Number of subjects: 144
Study 21494336 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS) at doses of 10, 15, 20, and 30 mg worn for 9 hours per day for 7 weeks
Number of subjects: 305
Study 21494336 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS)
Number of subjects: 305
Study 21494336 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch testing for DRS scores ≥ 6 or persistent DRS scores ≥ 4
Number of subjects: 305
Study 21494337 — intervention group
Group type: EXPERIMENTAL
Intervention: P4 screener
Number of subjects: 559
Study 21494838 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4877 at 16 mg/day (maximum tolerated dose)
Number of subjects: 0
Study 21494838 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4877 at 4 mg/day
Number of subjects: 0
Study 21495023 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 40
Study 21496339 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT survivors completing a series of questionnaires annually.
Number of subjects: 0
Study 21496339 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measures including: Medical Outcomes Study SF-36, FACIT - General, FACIT-Fatigue, FACIT-Spiritual, Psychosocial Adjustment to Illness Scale, Rotterdam Symptom Checklist-Revised, Pittsburgh Sleep Quality Index.
Number of subjects: 0
Study 21497495 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic counselling and BRCA genetic testing
Number of subjects: 2000
Study 21497773 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin-based induction chemotherapy
Number of subjects: 60
Study 21498606 — intervention group
Group type: EXPERIMENTAL
Intervention: Humanized anti-CD11a antibody treatment (weekly subcutaneous for 16 weeks)
Number of subjects: 6
Study 21498612 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal scanning laser ophthalmoscopy (cSLO) imaging modalities
Number of subjects: 458
Study 21498612 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundus camera photographs
Number of subjects: 458
Study 21498612 — intervention group
Group type: EXPERIMENTAL
Intervention: cSLO imaging
Number of subjects: 458
Study 21498612 — intervention group
Group type: EXPERIMENTAL
Intervention: FAF imaging
Number of subjects: 458
Study 21498612 — intervention group
Group type: EXPERIMENTAL
Intervention: IR imaging
Number of subjects: 458
Study 21498612 — intervention group
Group type: EXPERIMENTAL
Intervention: BR imaging
Number of subjects: 458
Study 21498612 — intervention group
Group type: EXPERIMENTAL
Intervention: RF imaging
Number of subjects: 458
Study 21498612 — intervention group
Group type: EXPERIMENTAL
Intervention: CF imaging
Number of subjects: 458
Study 21498612 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-field FAF images
Number of subjects: 458
Study 21499828 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer EHR with robust clinical decision support
Number of subjects: 17
Study 21501477 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin Skin Test (TST)
Number of subjects: 166
Study 21501477 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFERON®-TB Gold In-Tube assay (QFT-IT)
Number of subjects: 166
Study 21502084 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg twice daily for 8 days
Number of subjects: 12
Study 21502280 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of clinical guidelines for CVD prevention
Number of subjects: 806
Study 21502280 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC guidelines
Number of subjects: 806
Study 21502280 — intervention group
Group type: EXPERIMENTAL
Intervention: Global risk calculation tools
Number of subjects: 806
Study 21502280 — intervention group
Group type: EXPERIMENTAL
Intervention: Written charts
Number of subjects: 806
Study 21502280 — intervention group
Group type: EXPERIMENTAL
Intervention: SCORE equation
Number of subjects: 806
Study 21502280 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived limitations of global risk equations
Number of subjects: 806
Study 21502280 — intervention group
Group type: EXPERIMENTAL
Intervention: Local healthcare framework sufficiency for primary prevention
Number of subjects: 806
Study 21502280 — intervention group
Group type: EXPERIMENTAL
Intervention: Local healthcare framework sufficiency for secondary prevention
Number of subjects: 806
Study 21502553 — intervention group
Group type: EXPERIMENTAL
Intervention: Belinostat administered intravenously at 1 g/m(2) on days 1 to 5 of a 21-day cycle until disease progression or development of intolerance.
Number of subjects: 41
Study 21502650 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative myocardial infarction (MI)
Number of subjects: 8351
Study 21502650 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with perioperative MI
Number of subjects: 8351
Study 21502650 — intervention group
Group type: COMPARATOR
Intervention: Patients without perioperative MI
Number of subjects: 8351
Study 21502650 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ischemic symptoms
Number of subjects: 8351
Study 21502650 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without ischemic symptoms
Number of subjects: 8351
Study 21502953 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1521498 (0.4-100 mg)
Number of subjects: 0
Study 21502953 — intervention group
Group type: COMPARATOR
Intervention: NTX (2-50 mg)
Number of subjects: 0
Study 21503856 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg pegnivacogin
Number of subjects: 0
Study 21503856 — intervention group
Group type: EXPERIMENTAL
Intervention: anivamersen (RB007)
Number of subjects: 0
Study 21504290 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide monotherapy
Number of subjects: 0
Study 21504563 — intervention group
Group type: EXPERIMENTAL
Intervention: Masitinib (3 or 6 mg/kg/day)
Number of subjects: 34
Study 21504563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 21504774 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 μg HA/AS03(A)
Number of subjects: 454
Study 21504774 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.9 μg HA/AS03(B)
Number of subjects: 454
Study 21505722 — intervention group
Group type: EXPERIMENTAL
Intervention: Certoparin 3,000U anti Xa o.d.
Number of subjects: 189
Study 21505722 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) 5,000 IU t.i.d.
Number of subjects: 189
Study 21507261 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal allergen challenge (NAC) for 4 consecutive days after a control challenge with normal saline.
Number of subjects: 32
Study 21507261 — intervention group
Group type: COMPARATOR
Intervention: Control challenge (normal saline).
Number of subjects: 32
Study 21507261 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal allergen challenge (NAC) for 4 consecutive days.
Number of subjects: 32
Study 21508089 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrins and leucine (0.035 g . kg(-1) . h(-1))
Number of subjects: 11
Study 21508089 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrins (0.25 g . kg(-1) . h(-1))
Number of subjects: 11
Study 21508120 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-myeloablative conditioning and allogeneic hematopoietic cell transplantation with post-grafting imatinib for Philadelphia chromosome-positive disease
Number of subjects: 51
Study 21508120 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-myeloablative conditioning and allogeneic hematopoietic cell transplantation
Number of subjects: 51
Study 21508125 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow analysis in patients with MonoMAC
Number of subjects: 18
Study 21508125 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytogenetic analysis in patients with MonoMAC
Number of subjects: 18
Study 21508125 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of plasma cells in patients with MonoMAC
Number of subjects: 18
Study 21508125 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell large granular lymphocyte populations in patients with MonoMAC
Number of subjects: 18
Study 21508125 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosomal breakage studies and sequencing in patients with MonoMAC
Number of subjects: 18
Study 21508251 — intervention group
Group type: EXPERIMENTAL
Intervention: Body talk among social contacts
Number of subjects: 60
Study 21508413 — intervention group
Group type: EXPERIMENTAL
Intervention: ⁹⁰Y-ibritumomab tiuxetan, fludarabine, and 2 Gy total body irradiation
Number of subjects: 40
Study 21508633 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR(Cys)
Number of subjects: 476
Study 21508633 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR(Cr)
Number of subjects: 476
Study 21508633 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuminuria
Number of subjects: 476
Study 21511109 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional myocardial dysfunction (RMD)
Number of subjects: 4510
Study 21513539 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and feedback intervention for healthcare providers
Number of subjects: 0
Study 21513539 — intervention group
Group type: COMPARATOR
Intervention: Guidelines distribution at both sites
Number of subjects: 0
Study 21513539 — intervention group
Group type: EXPERIMENTAL
Intervention: Unit-level feedback at the intervention site
Number of subjects: 0
Study 21513539 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre/post surveys of awareness and familiarity (knowledge)
Number of subjects: 0
Study 21513761 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV), single intranasal dose.
Number of subjects: 200
Study 21514658 — intervention group
Group type: EXPERIMENTAL
Intervention: Rechallenged with bites of five mosquitoes infected with P falciparum
Number of subjects: 6
Study 21514658 — intervention group
Group type: COMPARATOR
Intervention: Control group (newly recruited malaria-naive volunteers)
Number of subjects: 6
Study 21514658 — intervention group
Group type: EXPERIMENTAL
Intervention: In-vitro assays of immune volunteers
Number of subjects: 6
Study 21514658 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events in immune volunteers
Number of subjects: 6
Study 21516509 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-0325901 at 20 mg BID for 21 days followed by 7 days off (initial dose)
Number of subjects: 13
Study 21516509 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-0325901 at 15 mg BID (changed dose)
Number of subjects: 13
Study 21516509 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-0325901 (overall treatment)
Number of subjects: 13
Study 21518043 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic questionnaire and algorithm
Number of subjects: 110
Study 21518043 — intervention group
Group type: COMPARATOR
Intervention: Reference diagnostic test method (RTM)
Number of subjects: 110
Study 21518322 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell therapy (30 mL of bone marrow cultured for MSC growth, injected into one knee)
Number of subjects: 4
Study 21518586 — intervention group
Group type: EXPERIMENTAL
Intervention: Firebird sirolimus-eluting stent (SES)
Number of subjects: 1029
Study 21518864 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study 21518864 — intervention group
Group type: COMPARATOR
Intervention: Antiinflammatory agents
Number of subjects: 0
Study 21518985 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapaquistat 100 mg daily
Number of subjects: 6151
Study 21518985 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapaquistat 100 mg daily with statin
Number of subjects: 6151
Study 21518985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6151
Study 21519909 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 0
Study 21523798 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning (RIC) with busulfan, fludarabine, and antithymocyte globulin
Number of subjects: 128
Study 21524193 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum insulin secretion relative to serum glucose after a glucose challenge
Number of subjects: 29
Study 21524193 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum adiponectin
Number of subjects: 29
Study 21524193 — intervention group
Group type: EXPERIMENTAL
Intervention: Model OL = 232 - 34.9(ln[ratio insulin/glucose]) - 1.4(adiponectin)
Number of subjects: 29
Study 21524299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring (ABPM) and clinic blood pressure monitoring
Number of subjects: 300
Study 21524299 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid ultrasound to evaluate intima-media thickness (IMT)
Number of subjects: 300
Study 21524299 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal arteriovenous index measurement
Number of subjects: 300
Study 21524299 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse wave velocity (PWV) and ankle-brachial index
Number of subjects: 300
Study 21524299 — intervention group
Group type: EXPERIMENTAL
Intervention: Software for measuring retinal vessel thickness and estimating arteriovenous index
Number of subjects: 300
Study 21524299 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial dysfunction markers and other clinical parameters (lipids, creatinine, microalbuminuria, blood glucose, HbA1c, blood insulin, high sensitivity C-reactive protein)
Number of subjects: 300
Study 21524303 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based learning kit plus monthly phone calls
Number of subjects: 201
Study 21524303 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based learning kit plus coaching
Number of subjects: 201
Study 21524303 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based learning kit plus face-to-face meetings
Number of subjects: 201
Study 21524303 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based learning kit plus all three methods (monthly phone calls, coaching, face-to-face meetings)
Number of subjects: 201
Study 21524303 — intervention group
Group type: COMPARATOR
Intervention: Monthly phone calls (lowest cost intervention)
Number of subjects: 201
Study 21524447 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvest by experienced technicians (n=55)
Number of subjects: 95
Study 21524447 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvest by novice technicians (n=30)
Number of subjects: 95
Study 21524447 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvest (both experienced and novice)
Number of subjects: 95
Study 21524447 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvest with at least 4 intimal or medial dissections
Number of subjects: 95
Study 21524447 — intervention group
Group type: COMPARATOR
Intervention: Open vein harvest (n=10)
Number of subjects: 95
Study 21525172 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus
Number of subjects: 16
Study 21525850 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% glucose and 0.25% L-carnitine
Number of subjects: 4
Study 21525850 — intervention group
Group type: COMPARATOR
Intervention: 2.5% glucose solutions
Number of subjects: 4
Study 21525850 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine added to endothelial cells in culture
Number of subjects: 4
Study 21525850 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine in peritoneal dialysis solution
Number of subjects: 4
Study 21527026 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (anti-IgE therapy)
Number of subjects: 9
Study 21527065 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus capecitabine
Number of subjects: 52
Study 21527127 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief eclectic psychotherapy
Number of subjects: 0
Study 21527127 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 21527129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine infusion
Number of subjects: 1
Study 21527169 — intervention group
Group type: EXPERIMENTAL
Intervention: Young men during energy balance
Number of subjects: 32
Study 21527169 — intervention group
Group type: COMPARATOR
Intervention: Older men during energy balance
Number of subjects: 32
Study 21527169 — intervention group
Group type: EXPERIMENTAL
Intervention: Young men after underfeeding
Number of subjects: 32
Study 21527169 — intervention group
Group type: COMPARATOR
Intervention: Older men after underfeeding
Number of subjects: 32
Study 21527169 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum energy intake after underfeeding
Number of subjects: 32
Study 21529978 — intervention group
Group type: EXPERIMENTAL
Intervention: Glitazone treatment
Number of subjects: 102
Study 21530362 — intervention group
Group type: EXPERIMENTAL
Intervention: nelfilcon A with enhanced lubricating agents (ELDD)
Number of subjects: 10
Study 21530362 — intervention group
Group type: EXPERIMENTAL
Intervention: daily disposable contact lenses (DD)
Number of subjects: 10
Study 21530362 — intervention group
Group type: COMPARATOR
Intervention: no contact lenses
Number of subjects: 10
Study 21530445 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion from tacrolimus to cyclosporine
Number of subjects: 39
Study 21531600 — intervention group
Group type: EXPERIMENTAL
Intervention: tesamorelin
Number of subjects: 13
Study 21531821 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg/d (4 weeks on/2 weeks off)
Number of subjects: 26
Study 21531880 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Function Questionnaire (LFQ) with a cut point of 18 or less
Number of subjects: 1575
Study 21531880 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients scoring 18 or less on the LFQ
Number of subjects: 1575
Study 21531880 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 50 years or older scoring 18 or less on the LFQ
Number of subjects: 1575
Study 21533229 — intervention group
Group type: EXPERIMENTAL
Intervention: MRKAd5 HIV-1 gag vaccine
Number of subjects: 70
Study 21533229 — intervention group
Group type: COMPARATOR
Intervention: Ad5 empty vector
Number of subjects: 70
Study 21533229 — intervention group
Group type: EXPERIMENTAL
Intervention: Gag-specific T cells
Number of subjects: 70
Study 21536060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin levels
Number of subjects: 308
Study 21536060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin levels in women
Number of subjects: 308
Study 21536060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin levels in lean individuals (BMI < 22.6 kg/m(2))
Number of subjects: 308
Study 21536060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin levels in heavier individuals (BMI > 22.6 kg/m(2))
Number of subjects: 308
Study 21536060 — intervention group
Group type: EXPERIMENTAL
Intervention: Restraint (R) and disinhibition (D)
Number of subjects: 308
Study 21538322 — intervention group
Group type: EXPERIMENTAL
Intervention: Givinostat (ITF2357) administered orally at a dosage of 1.5 mg/kg/day for up to 12 weeks
Number of subjects: 17
Study 21540203 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted influenza A/California/7/2009(H1N1) virus-like strain flu vaccine
Number of subjects: 1668
Study 21540460 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic infusion of in vitro-generated donor T cells reactive against CML-associated antigens
Number of subjects: 14
Study 21540460 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8(+) T cells displaying marked cytotoxic activity
Number of subjects: 14
Study 21541021 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 1995
Study 21541021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1995
Study 21541799 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression anastomosis using ColonRing™
Number of subjects: 62
Study 21543424 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 6621
Study 21543530 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 2400 kcal/d
Number of subjects: 21
Study 21543530 — intervention group
Group type: COMPARATOR
Intervention: Diet with 3400 kcal/d
Number of subjects: 21